DVAX - Dynavax Technologies Corp.
IEX Last Trade
11.21
-0.050 -0.446%
Share volume: 1,090,588
Last Updated: Fri 30 Aug 2024 10:00:00 PM CEST
Research and Development in Biotechnology (except Nanobiotechnology):
0.21%
PREVIOUS CLOSE
CHG
CHG%
$11.26
-0.05
-0.44%
Fundamental analysis
13%
Profitability
7%
Dept financing
25%
Liquidity
75%
Performance
0%
Performance
5 Days
-2.35%
1 Month
-1.49%
3 Months
-5.08%
6 Months
-13.36%
1 Year
-23.52%
2 Year
-1.06%
Key data
Stock price
$11.21
DAY RANGE
N/A - N/A
52 WEEK RANGE
$9.74 - $15.15
52 WEEK CHANGE
-$0.23
DIVIDEND
N/A
EX-DIVIDEND DATE
N/A
NEXT EARNINGS DATE
10/31/2024
Company detail
CEO: Ryan Spencer
Region: US
Website: http://www.dynavax.com/
Employees: 344
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
Region: US
Website: http://www.dynavax.com/
Employees: 344
IPO year: -
Issue type: Common Stock
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services
dynavax technologies corporation is a clinical-stage biopharmaceutical company that develops products to prevent and treat infectious and inflammatory diseases and cancer. our clinical-stage product candidates include: phase 3 heplisav-b ™ adult hepatitis b vaccine phase 1/2 cancer immunotherapy phase 2 asthma therapy - partnered with astrazeneca in europe, dynavax manufactures hepatitis b surface antigen for heplisav-b.
Recent news